SCHEDULE: Biogen to Acquire Apellis Pharmaceuticals in $41 Billion Deal

Biogen Inc. announced its definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right (CVR) per share, valuing the company at approximately $41 billion.

Summary

• Biogen Inc. has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc.
• The acquisition will be conducted through a tender offer by Biogen's subsidiary, Aspen Purchaser Sub, Inc.
• The offer price is $41.00 per share in cash, plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential future payments of up to $4.00 in cash upon the achievement of specified sales milestones for SYFOVRE® and related products.
• Specifically, $2.00 per CVR is payable upon achieving $1.5 billion in annual net sales of SYFOVRE® and related products in 2027-2030, and another $2.00 per CVR upon achieving $2.0 billion in annual net sales in 2027-2031.
• The transaction is expected to close in the second quarter of 2026.
• Upon closing, Apellis will become a privately held company, and its common stock will no longer be listed on a public market.
• Biogen expects to finance the merger with a combination of cash on hand and term loan proceeds.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Apellis shareholders due to the cash offer and potential CVR upside, indicating a strong valuation for the company's assets.

Positives

• Biogen is acquiring Apellis, a company with a drug for geographic atrophy (GA) associated with age-related macular degeneration (AMD) and paroxysmal nocturnal hemoglobinuria (PNH).
• The deal includes a CVR component, allowing Apellis shareholders to benefit from future sales success of SYFOVRE®.
• The upfront cash payment provides immediate value to Apellis shareholders.
• The acquisition is structured as a tender offer followed by a short-form merger, indicating a streamlined process.
• The transaction is expected to be completed relatively quickly, in the second quarter of 2026.

Negatives

• The CVR payments are contingent on future sales performance, introducing uncertainty for a portion of the potential value.
• Apellis will cease to be a publicly traded company, limiting future investment opportunities for public market participants.
• The filing does not provide specific financial metrics for Apellis's current performance, focusing on the transaction terms.

Risks

• The achievement of CVR milestones is not guaranteed and depends on market adoption and sales performance of SYFOVRE®.
• Regulatory approvals and market access for SYFOVRE® are critical for the CVRs to have value.
• Integration risks associated with combining Biogen and Apellis operations.
• Potential for delays in closing the transaction due to regulatory reviews or other unforeseen circumstances.

Future Outlook

The future outlook for Apellis shareholders is tied to the success of the acquisition by Biogen and the potential achievement of sales milestones for SYFOVRE® which could result in additional payments through the CVRs. Biogen's financial statements will incorporate Apellis's results post-acquisition.

Industry Context

StockSavvy.ai notes that this acquisition reflects a trend of consolidation within the biotechnology sector, particularly in areas with significant unmet medical needs like ophthalmology. Biogen's move to acquire Apellis, a company with a promising drug for geographic atrophy, signals a strategic expansion into a potentially lucrative market segment.

Stakeholder Impact

• Shareholders of Apellis will receive $41.00 per share in cash plus a CVR, providing immediate value and potential future upside.
• Employees of Apellis may experience changes in roles and benefits as part of the integration into Biogen.
• Patients who use or may use SYFOVRE® will continue to have access to the treatment, with potential for Biogen's broader resources to support its development and commercialization.
• Creditors and suppliers of Apellis will have their contracts and obligations reviewed and potentially assumed by Biogen.

Next Steps

• Commencement of the tender offer by Aspen Purchaser Sub, Inc.
• Filing of Schedule TO and Schedule 14D-9 with the SEC.
• Regulatory reviews and approvals.
• Closing of the tender offer and subsequent merger.

Key Dates

Recommendation

For existing Apellis shareholders, the recommendation is to hold and tender shares into the offer, as the $41.00 cash plus CVR represents a significant premium and potential upside. For investors not currently holding Apellis, the stock is no longer publicly traded post-acquisition, making a buy recommendation irrelevant.

Keywords

Apellis Pharmaceuticals, Biogen, Acquisition, Tender Offer, Merger, CVR, SYFOVRE, Geographic Atrophy, Age-Related Macular Degeneration, Pharmaceuticals, Biotechnology